These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12872372)

  • 1. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
    Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on the use of imatinib mesylate.
    Sawyers CL
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
    Richardson MW; Grewal SS
    Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
    Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
    Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib and chronic-phase leukemias.
    Boros LG; Lee WN; Cascante M
    N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
    [No Abstract]   [Full Text] [Related]  

  • 8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
    Breccia M; Santopietro M; Loglisci G; Stagno F; Cannella L; Carmosino I; Alimena G
    Leuk Res; 2010 Aug; 34(8):e224-5. PubMed ID: 20356624
    [No Abstract]   [Full Text] [Related]  

  • 12. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
    Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
    [No Abstract]   [Full Text] [Related]  

  • 13. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
    Defina M; Gozzetti A; Rondoni M; Aprile L; Ippoliti M; Chitarrelli I; Lauria F; Bocchia M
    Leuk Res; 2010 Aug; 34(8):e215-6. PubMed ID: 20334915
    [No Abstract]   [Full Text] [Related]  

  • 14. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 15. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction: chronic myelogenous leukemia (CML).
    Jabbour E; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
    [No Abstract]   [Full Text] [Related]  

  • 17. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
    Bornhäuser M; Pursche S; Bonin M; Freiberg-Richter J; Jenke A; Illmer T; Ehninger G; Schleyer E
    J Clin Oncol; 2005 Jun; 23(16):3855-6; author reply 3857-8. PubMed ID: 15923584
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I
    Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
    [No Abstract]   [Full Text] [Related]  

  • 20. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.